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A b s t r a c t
The common use of stents, including antiproliferative drug-eluting stents, has been a major breakthrough in invasive cardiology. 
Nowadays, a change in the clinical presentation of patients treated with percutaneous coronary intervention (PCI) is observed. 
The typical clinical characteristics now include advanced age, diabetes, chronic kidney disease, heart failure, and multilevel 
atherosclerosis. Age, diabetes, and chronic kidney disease are the main predictors of coronary artery calcifications. Severe 
coronary artery calcifications are the main factor limiting the efficacy of PCI. Successful stent implantation is challenging in 
the presence of calcifications, because it is difficult to achieve full stent expansion and proper stent apposition. Therefore, it 
is necessary to adequately prepare the lesion before stent implantation. This document presents the technique of rotational 
atherectomy (rotablation) as well as indications for and contraindications to the procedure, along with its possible complica-
tions and their prevention. Training in rotablation for operators as well as reimbursement policy for the procedure in Poland 
are also discussed.
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EXPERTS’ OPINIONS AND POSITION PAPERS
INTRODUCTION
Nowadays, patients undergoing percutaneous coronary 
interventions (PCIs) are quite different in terms of their clini-
cal and angiographic characteristics than those subjected to 
PCIs in the past. Currently, the typical clinical features of 
these patients are advanced age, diabetes, chronic kidney 
disease, heart failure, and multilevel atherosclerosis [1, 2]. 
These factors contribute to the severity of atherosclerotic 
lesions as well as the procedural risk [3, 4]. According to 
current recommendations of cardiological societies, the final 
decision on the method of revascularisation in patients with 
stable ischaemic heart disease and complex coronary artery 
lesions (especially in the presence of left main stenosis and/or 
multivessel disease) should be made by a multidisciplinary 
team including a cardiac surgeon, an interventional cardiolo-
gist, and a cardiologist (Heart Team) [5].
Age, diabetes, and chronic kidney disease are the 
main predictors of coronary artery calcifications. Severe 
calcifications are the main factor limiting the efficacy of PCI 
procedures, both in terms of early and long-term outcomes 
[6, 7]. The common use of stents, including antiproliferative 
drug-eluting stents (DESs), has been a breakthrough in invasive 
cardiology. For a successful stent implantation, it is essential 
to achieve full stent expansion and its proper adhesion to 
the vascular wall (apposition). The presence of calcifications 
makes stent implantation difficult or even impossible, so 
adequate preparation of the lesion before the procedure is 
necessary. Inadequate apposition increases the risk of in-stent 
thrombosis and restenosis.
ROTATIONAL ATHERECTOMY (ROTABLATION) 
Rotational atherectomy (RA), which was introduced into clini-
cal practice in 1988, is the most effective method of calcified 
plaque modification [7–9]. RA, also known as rotablation, 
extends the coronary artery lumen by removing part of the 
atheromatous plaque and its softening, thus facilitating vessel 
dilatation. The plaque is removed by breaking it into micro-
particles of < 10 µm in size (approximately 5 µm on aver-
age), which enables their free passage through the coronary 
microcirculation. First, a metal guidewire with a diameter of 
0.009 inches is introduced into the distal bed of the target 
vessel. Then, a diamond-coated elliptical burr at the tip of 
a flexible drive shaft is advanced coaxially over the guidewire. 
The burr, rotating at a speed of 130,000–180,000 rpm, ablates 
more than 98% of the plaque into the microparticles. The burr 
is driven by an air turbine using compressed gas to generate 
the high rotational speed [8–10]. The device components 
include gas supply with compressed air or nitrogen (> 6 atm), 
which is connected to the control console, air turbine, and 
foot pedal activating the drive. The disposable parts include 
the burr and the 0.009-inch steel guidewire (with a 0.014-
inch tip) connected to the advancer. The tip is thicker to 
allow a removal of the burr together with the guidewire in 
case of damage. The burr is placed in a special sheath that 
enables a continuous administration of normal saline and 
various drugs to the site of ablation. The device is produced 
by Boston Scientific, the only manufacturer of such devices 
until 2007. In 2007, a system for so called orbital atherectomy 
(Orbital Atherectomy System, Cardiovascular System, Inc., St. 
Paul, MN, USA) was developed, which works in a similar way 
but has a slightly different ablation element, also covered with 
a diamond crown. The system is set in a rotational motion 
with a pneumatic or an electric drive. Its working speed is 
between 80,000 and 120,000 rpm. The first published results 
for the use of this system are promising [11, 12].
ROTATIONAL ATHERECTOMY PROCEDURE  
PROTOCOL AND PERIPROCEDURAL  
PHARMACOTHERAPY
Patients undergoing RA should be prepared in the same way as 
any other patient undergoing a PCI procedure. Dual antiplatelet 
therapy should be administered early enough to inhibit platelet 
function [5]. Before the procedure, use of sedative drugs and 
preparation of vascular access are advisable. As most patients 
referred for RA are at older age and have multiple comorbidities, 
including diabetes and chronic kidney disease, it is important 
to maintain normal glucose levels in the periprocedural period 
and prevent contrast-induced nephropathy [13].
VASCULAR ACCESS AND GUIDEWIRES
The choice of a vascular access depends on the experience 
of the centre and the burr size. Standard burr sizes are 1.25, 
1.5, and 1.75 mm, and they are compatible with 6 Fr (French) 
guiding catheters. There is basically no need to use guiding 
catheters greater than 7 Fr because the burrs over 2 mm are 
rarely used, which enables the use of a radial access in the 
majority of RA procedures. Coaxial positioning of the guid-
ing catheter in the coronary artery ostium is essential for the 
RA procedure itself and its subsequent stages. An interesting 
modification of the radial access is the use of sheathless guid-
ing catheters, which have a greater internal diameter while 
causing less damage to the vessel. An additional advantage is 
their hydrophilicity, which facilitates their advancement even 
through a narrow radial artery. However, these guiding catheters 
have a weak support, which may limit stent delivery [14, 15]. 
Another option is the use of a thin-walled sheath dedicated for 
radial-access procedures, which enables the use of a standard 
guiding catheter with a one-size greater diameter (i.e. for the 
6-Fr sheath, the 7-Fr guiding catheter can be used).
The RA procedure requires the use of dedicated guide-
wires of 330 cm in length, which come in two types depending 
on their stiffness (Floppy and Extra Support). Their introduc-
tion to the distal segment of the artery is much more difficult 
than with a standard PCI guidewire. To solve this problem, 
microcatheters or over-the-wire balloon catheters are used, 
which allow a replacement of a standard guidewire for PCI 
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with a guidewire for RA. Next, a suitable burr size has to be 
selected and advanced to the target lesion. Current guidelines 
and leading centres recommend plaque modification, which 
involves the use of a single burr with a size of < 0.7 of the 
vessel diameter [9, 10]. Plaque modification is associated with 
a lower complication rate than the previously used plaque 
debulking technique aimed at removing the highest possible 
volume of the atheromatous plaque [16, 17]. However, the 
increasingly common strategy is to use the smallest possible 
burr size (1.25 mm) to incise the atheromatous plaque, which 
is believed to reduce the risk of complications. This technique 
is usually effective because the target vessels are narrow and 
severely calcified along their entire length. The rotational 
speed should range between 130,000 and 180,000 rpm, and 
it is recommended to advance the burr in a smooth pecking 
motion, with a duration of an individual burr run between 
10 and 30 s. The burr should be retreated from the lesion at 
the end of each cycle to avoid its entrapment. The speed of 
the burr should be monitored at all times, and in the case of 
deceleration > 5000 rpm, the pressure on the lesion should 
be reduced, the burr should be retreated from the lesion, 
and the individual burr run should be stopped if needed [9, 
17]. During rotablation, thermal energy is produced, which 
increases the temperature in the lesion by several Celsius 
degrees. Long run times with a considerable reduction of 
rotational speed (by several thousand rpm) result in a local 
increase in the temperature even by more than 10°C [18, 19]. 
In case of resistance in the lesion, the speed can be increased 
up to 180,000–200,000 rpm, with a simultaneous reduc-
tion in individual time runs to avoid generating too much 
heat. Moreover, high speed increases platelet activation. 
Both these effects contribute to periprocedural myocardial 
necrosis [19, 20]. Ablation of tortuous lesions should be 
performed at lower burr speed (100,000–120,000 rpm) and 
sizes, which reduces the risk of vessel perforation [21]. An 
important component of the procedure is the use of rotab-
lation flushing cocktail. Its composition varies, but it always 
includes heparin, nitroglycerin, verapamil or other drugs from 
this class, or nicorandil [22]. The cocktail infusion reduces 
the risk of slow-flow/no-reflow phenomena and the rate of 
periprocedural myocardial infarction (MI) [23, 24]. Another 
way to reduce blood flow disturbances during RA is intrave-
nous administration of glycoprotein IIb/IIIa platelet receptor 
antagonists. The most thoroughly investigated drug of this 
class is abciximab [25]. Currently, this drug class is reserved 
mainly for bail-out use after evaluation of individual risk of 
haemorrhagic and ischaemic complications. The available 
data indicate that the use of bivalirudin, a direct thrombin 
inhibitor, does not offer a clinical benefit in comparison with 
a routinely used unfractionated heparin [26].
After a successful rotablation the course of the procedure 
is similar to that in other complex PCIs. The subsequent stages 
are performed using classic extra-support guidewires for PCI, 
which are advanced parallel to the RA guidewire or they are 
introduced to replace the RA guidewire using a microcath-
eter or over-the-wire balloon. Before stent deployment, the 
rotablation guidewire should be retracted to avoid its entrap-
ment in the vessel. Balloon post-dilatations are performed 
using non-compliant balloons or balloon catheters designed 
for very high pressures (even above 30 atm). In the case of 
a resistant lesion, another ablation with a larger-sized burr can 
be considered. The one-burr approach is also economically 
reasonable, especially in countries where the RA procedure 
alone is not reimbursed or the reimbursement is insufficient 
(in Poland, there had been no reimbursement until 1 Janu-
ary 2017, and since 1 January 2017, there has been partial 
reimbursement). There is much controversy over the man-
agement algorithm after successful passage with the first burr 
due to a lack of scientific evidence. According to a European 
expert consensus on RA, in the case of low-pressure-inflated 
balloon or incomplete balloon expansion, rotablation should 
be continued with a larger-sized burr [10]. This consensus 
resulted from a compromise between two expert groups with 
opposing views. The first group considered the use of another 
larger-sized burr to be the safest strategy, while the other stated 
that high-pressure inflations with or without cutting balloons 
are sufficient in most cases. However, high-pressure infla-
tion may be insufficient and may cause dissection, which 
represents a contraindication to further rotablation. It is thus 
possible to use scoring and cutting balloons, which are cur-
rently not reimbursed in Poland [9, 21, 27]. The final stage 
of a PCI with RA is stent implantation. Because of severe 
calcifications and long lesions, stent delivery is often difficult. 
For the subsequent RA stages to be successful, it is important 
to use a suitable guiding catheter and pay attention to its 
coaxial positioning in the coronary artery ostium. Moreover, 
the shape of the catheter should be adjusted to the target 
vessel. In case of any difficulties in stent delivery, the use of 
a “mother-and-child” technique is recommended [28]. 
Another issue is temporary pacing during RA. During the 
procedure, a neurohumoral response is induced, which leads 
to bradycardia [8, 29]. When RA was introduced into clini-
cal practice, temporary pacing was obligatory during all RA 
interventions. However, the increasing experience of teams 
performing rotablation and a comprehensive assessment of 
procedure outcomes, including periprocedural complications, 
have led to a change in the approach. Despite the lack of 
uniform recommendations, it seems reasonable to state that 
preventive pacing is not necessary. In case of bradycardia 
during the procedure, the use of atropine and pacing are 
recommended [9, 21, 29]. This statement is based on the 
results of two large studies published in 2012 and 2014 [30, 
31]. The analyses included over 5000 patients treated with 
RA. In a British registry [31], which analysed the outcomes 
of RA in 2152 patients, temporary pacing was necessary in 
as few as 1.3% of individuals, as compared with 0.3% in 
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patients undergoing PCI without RA. In our opinion, preven-
tive implantation of a temporary pacing electrode can be 
justified only in cases when RA is performed in a dominant 
right coronary artery with long lesions.
The Expert Group of the Association of Cardiovascular 
Interventions of the Polish Society of Cardiology (Asocjacja 
Interwencji Sercowo-Naczyniowych Polskiego Towarzystwa 
Kardiologicznego — AISN PTK) recommends performing 
RA according to proposed protocols for patient preparation 
as well as for the selection of a vascular access, guiding 
catheter, and burr size. During the procedure, it is impor-
tant to apply short burr run times, monitor the rotational 
speed, and use rotablator flushing cocktail. The procedure 
should be started at a lower rotational speed, and, if inef-
fective, it should be increased and/or the smallest-sized 
burr should be used. Strict compliance with these recom-
mendations will prevent or reduce complications.
INDICATIONS FOR AND CONTRAINDICATIONS 
TO ROTATIONAL ATHERECTOMY.  
PREVENTION OF COMPLICATIONS
Stent implantation in a lesion that is resistant to balloon dilata-
tion is contraindicated and will not result in vessel dilatation. 
RA procedures are performed most often after a previous PCI 
failure due to inability to cross the lesion with the smallest 
balloon or adequately dilate the lesion with a high-pressure 
balloon (> 16 atm). The use of very high pressure increases 
the risk of vessel perforation, while rescue delivery of a stent 
graft to a long calcified lesion may be impossible. This in-
dication for rotablation has a IC class of recommendation 
in the 2010 European Society of Cardiology and European 
Association for Cardio-Thoracic Surgery guidelines on cardiac 
revascularisation [32]. In these indications, rotablation is the 
only effective percutaneous treatment. Rotablation in mild 
or moderate coronary artery calcifications does not provide 
satisfactory outcomes and is associated with an increased risk 
of complications [9, 21]. Therefore, it is crucial to evaluate the 
degree of calcifications before considering patients for RA. Se-
vere calcifications are diagnosed when they can be identified 
on an angiographic image before contrast administration into 
the artery lumen, and they usually involve both walls of the 
vessel. Moderate calcifications are visible only during the car-
diac cycle on coronary angiography. Computed tomography 
(CT), intravascular ultrasound (IVUS), and optical coherence 
tomography (OCT) can provide much more information on 
the localisation and severity of coronary artery calcifications 
[10, 33–35]. Tomey et al. [9] proposed an algorithm for the 
use of RA in clinical practice. Severe calcifications on coronary 
angiography are an indication for RA. If calcification is moder-
ate or cannot be determined by angiography, additional testing 
with IVUS or OCT is recommended. IVUS allows a precise 
assessment of the site of calcification (superficial, localised 
between the vessel lumen and media, versus deep, localised 
between the vascular media and adventitia) and the measure-
ment of the calcium arc. OCT additionally allows a precise 
quantitative evaluation of calcium layer thickness. Data ob-
tained with IVUS and OCT may facilitate the planning of a PCI 
procedure or may modify its course, but RA is beneficial mainly 
in patients with superficial calcifications involving > 227° of the 
vessel wall circumference and > 0.67-mm thickness on OCT 
[36, 37]. Indications for rotablation are presented in Table 1.
Rotational atherectomy facilitates a successful PCI proce-
dure in the case of complex lesions (type B2 and C accord-
ing to the American Heart Association/American College of 
Cardiology classification), including chronic total occlusions, 
ostial lesions, and bifurcations [38–42]. The ROSTER study 
[43] showed a beneficial effect of RA followed by adjunctive 
balloon dilatation at low pressure in the treatment of in-stent 
restenosis in comparison with high-pressure balloon angio-
plasty. On the other hand, the ARTIST study [44] revealed 
unfavourable outcomes of in-stent restenosis treatment with RA. 
RA significantly increased the rates of restenosis. These dis-
crepancies may result from using different inclusion criteria 
and different definitions of restenosis. Optimal treatment 
outcomes in these indications may be achieved by using 
IVUS-guided PCI. Other rare indications for using RA include 
inadequate expansion of a metal stent or bioresorbable 
scaffold (stent ablation and scaffold ablation) [45, 46]. 
Contraindications to RA are presented in Table 2.
Although vein graft stenosis is an absolute contraindica-
tion to RA, ostial stenosis after aortic or coronary artery bypass 
grafting may be an exception. In literature reports, the use 
of RA in patients with acute coronary syndromes (including 
ST-segment elevation MI) were involved vessels with a differ-
ent degree of thrombus burden. For example, in an Italian 
registry, 37% of the 1308 included patients underwent RA due 
to acute coronary syndromes [47]. Of course, the use of RA 
in these indications is often forced by PCI failure. PCI failure 
can also justify the use of RA in case of vessel dissection. In 
the presence of relative contraindications, RA procedures 
are performed more often and typically in cases when the 
patient does not consent to cardiac surgery or the surgical 
risk is too high. In selected high-risk patients with severe left 
ventricular dysfunction, mechanical circulatory support is 
a feasible option. The PROTECT II study [48] evaluated the use 
of intra-aortic counterpulsation and an Impella heart pump. 
Before deciding on the use of rotablation in these indications, 
a higher risk of severe complications should be considered 
and the patient’s consent should be obtained. Moreover, the 
eligibility of a patient to undergo these procedures should be 
assessed by a local Heart Team. 
Possible complications of RA, as well as their prevention 
and management, are listed in Table 3.
The Expert Group of the AISN PTK recommends RA 
in patients with refractory lesions that cannot be crossed 
or dilated with a balloon due to severe calcifications or 
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Table 1. Indications for rotational atherectomy
Classic indications Calcified or fibrotic stenosis that cannot be adequately dilated with a balloon 
Lesions that cannot be crossed with a balloon
Additional indications Severe calcifications on angiography, intravascular ultrasonography, and/or optical coherence 
tomography if there is a risk of balloon angioplasty or stent implantation failure
Severely calcified bifurcation lesions, including left main bifurcation
Chronic total occlusion (CTO) recanalisation after successful CTO crossing
Off-label indications Ablation of underexpanded stents or bioresorbable vascular scaffolds
Table 2. Contraindications to rotablation 
Absolute contraindications* Relative contraindications
Vein graft lesions
Thrombus 
Angiographic signs of vessel dissection
Severe left ventricular dysfunction (ejection fraction < 30%)
Severe three-vessel disease
Severe unprotected left main stenosis
Lesions of > 25 mm in length
Lesions of > 45 degrees in tortuous segments
*Rotablation is possible if other methods are ineffective
Table 3. Complications specific to rotablation procedures and preventive measures. Complications common for all types of  
percutaneous coronary interventions were not listed
Complication Preventive measures
Blood flow disturbances  




Short duration of individual burr runs (10–20 s)
Smaller burr size
Reduced rotational speed
Minimising decelerations during rotablation
Use of flushing cocktail
Glycoprotein IIb/IIIa receptor antagonists
Adenosine
Vessel perforation Plaque modification 
Smaller burr size
Reduced rotational speed in tortuous segments




Bradycardia, cardiac block Atropine, provisional temporary pacing
Preventive use of atropine before crossing the lesion
Preventive implantation of an intraventricular electrode in selected patients
Burr entrapment Short duration of individual burr runs 
Minimising decelerations during rotablation
Retraction of the burr from the lesion between individual burr runs
Balloon inflation proximal to burr entrapment to retrieve a stuck rotablator burr
Use of the “mother-and-child” technique, deep-vessel intubation with a guiding catheter (e.g. GuideLiner)
Cardiac surgery
Guidewire tip detachment Do not advance the burr to the distal end of the guidewire
Attempt removal with a loop snare
Stent implantation at the site of detachment
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fibrosis. RA should be considered as primary treatment 
in patients with severely calcified lesions. Centres without 
access to RA should refer their patients to selected refer-
ence centres.
The Expert Group of the AISN PTK does not recom-
mend RA in thrombotic lesions, vein grafts, or in the pres-
ence of vessel dissection. If other relative contraindications 
are present (ejection fraction < 30%, multivessel coronary 
artery disease, trunk stenosis), RA should be performed 
only in experienced centres with cardiac surgical facilities.
EFFICACY OF ROTATIONAL ATHEROTECTOMY: 
RESULTS OF CLINICAL TRIALS
Rotational atherectomy was introduced into clinical practice 
as an alternative option to standard balloon angioplasty. Early 
studies reported that RA had similar efficacy to percutaneous 
transluminal coronary angioplasty and other transcatheter 
interventions [49–51]. The procedure was soon proved to 
be useful in the treatment of patients with PCI failure, mainly 
those with long and severely calcified lesions [52, 53]. The 
ERBAC study [54], one of the important randomised trials 
evaluating different coronary interventions, compared RA 
with excimer laser angioplasty and conventional balloon 
angioplasty. Patients who underwent RA had a higher proce-
dural success rate and a significantly lower rate of composite 
endpoint (death, MI, or need for coronary artery bypass 
grafting) than those who underwent excimer laser angioplasty 
or conventional balloon angioplasty. In all groups restenosis 
rates were unacceptably high (> 50%). Hoffmann et al. [55] 
reported that the use of RA followed by stent implantation 
resulted in a significant improvement in early and long-term 
outcomes in comparison with PCI or stent implantation 
alone without RA in patients with long calcified lesions. The 
STRATAS [56] and CARAT [57] trials showed that RA does not 
provide better long-term angioplasty outcomes. The studies 
were important in that they showed that aggressive burr sizing 
(burr/artery ratio > 0.7) was associated with a significantly 
higher rate of perioperative complications. This aggressive 
strategy was aimed at reducing the plaque volume (plaque de-
bulking). The results of those trials raised controversy around 
RA and led to the search for new strategies. As a consequence, 
a technique known as plaque modification was developed, in 
which smaller-sized burrs were used. When combined with 
the introduction of DESs, the method again found its way into 
clinical practice to be used in selected populations. 
Numerous studies showed DES to be superior to bare 
metal stent implantation following RA procedures. DES 
implantation after rotablation is known as Rota-DES tech-
nique [58, 59]. In a large registry evaluating the results of 
Rota-DES in over 200 patients during a nine-month follow-up, 
Abdel-Wahab et al. [60] reported the cumulative incidence 
of major adverse cardiac events of 17.7% (death, 4.4%; MI, 
3.4%; target vessel revascularisation, 9.9%; and target lesion 
revascularisation, 6.8%). Only two incidents of late in-stent 
thrombosis (one definite and one probable) occurred. The 
authors concluded that the results were very promising in 
this patient population. The randomised ROTAXUS trial [61] 
compared two strategies of DES implantation in calcified coro-
nary artery lesions: with previous RA and with high-pressure 
balloon predilatation. Patients who did not undergo RA had 
worse outcomes and required a crossover into the RA group. 
The authors concluded that standard balloon predilatation is 
the method of choice in calcified lesions, with the use of RA 
in case of failure.
According to the Polish registry of invasive cardiology pro-
cedures (Ogólnopolski Rejestr Procedur Kardiologii Inwazyjnej 
— ORPKI), RA is widely available, mainly due to reimburse-
ment, and the number of procedures has increased each year 
due to population aging [62]. The number of periprocedural 
complications is higher for RA than for standard coronary 
angioplasty, but patients undergoing RA are generally at high 
operative risk [62, 63]. Moreover, according to Polish data, 
the use of RA in patients with acute coronary syndrome, 
including MI, does not increase the operative risk or worsen 
angiographic outcome [64, 65]. However, the patient’s 
prognosis depends not only on classic risk factors, such as 
heart failure, but also on whether they underwent complete 
revascularisation [63, 65].
ROTATIONAL ATHERECTOMY:  
TRAINING SYSTEM FOR OPERATORS
Rotational atherectomy is one of the most difficult and 
challenging procedures in interventional cardiology and is 
associated with an increased risk of complications due to 
complexity of the procedure alone, complexity of coronary 
artery lesions, as well as the complex clinical condition of 
patients treated with RA. Therefore, the requirements for 
operators and invasive cardiology centres should be much 
higher. In our opinion, RA procedures should be performed 
in catheterisation laboratories of a high referential level 
(B and C in Poland according to the AISN PTK) by independent 
invasive cardiologists  fulfilling AISN PTK criteria, who have 
performed independently at least 500 PCI procedures [66]. 
When the method is implemented in a new centre, the first 
procedures should be performed under supervision of an 
experienced operator.
The Expert Group of the AISN PTK recommends intro-
ducing a graded RA training programme for operators. The 
procedure can be performed by a qualified invasive car-
diologist who has obtained the AISN PTK certificate of an 
independent operator and who has performed at least 
500 procedures of coronary angioplasty. After completing 
theoretical and practical training (workshops, manufactur-
er trainings), it is recommended that the operator should 
perform at least 10 RA procedures (as the first or second 
operator) under supervision of an experienced operator. 
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It is recommended that RA procedures are performed by 
at least two certified doctors.
REIMBURSEMENT OF ROTATIONAL  
ATHERECTOMY PROCEDURE IN POLAND
At the request of the Board of the AISN PTK and the National 
Consultant of Cardiology, since 1 January 2017 the medical 
procedure “Coronary atherectomy — rotablation” has been 
included in the list of health care services available for reim-
bursement (number 5.53.01.0005004 in attachment 1c to 
the Regulation No. 38/2017/DSOZ of the President of the 
Polish National Health Fund of 29 May 2017) [67, 68]. The 
reimbursement of rotablation may be grouped with all types of 
PCI procedures, both in acute coronary syndromes and stable 
coronary artery disease, as well as with IVUS or fractional 
flow reserve assessment. The procedure can be reimbursed 
on condition that it is assigned an ICD-9 00.662 code for 
coronary atherectomy and one of the two following clinical 
indications are present: 1) severely calcified atheromatous 
lesions in the coronary artery, both in the native artery and in 
the neointima in patients with in-stent restenosis, that cannot 
be crossed or dilated with a balloon; or 2) severely calcified 
lesions on coronary angiography, IVUS, or OCT that do not 
allow adequate stent expansion [69].
The Expert Group of AISN PTK recommends that angio-
graphic images of RA performed during PCI are registered 
and archived and that clinical indications for RA and its 
reimbursement are noted in the patient’s medical records.
SUMMARY
The literature review of the history of RA since its introduction 
into clinical practice confirms its usefulness in facilitating PCIs 
for the treatment of calcifications of complex atherosclerotic 
lesions. Growing experience in the use of RA, a better un-
derstanding of plaque modification mechanisms, and the 
utilisation of the most experienced catheterisation laboratories 
have minimised the rate of complications. The new system 
of training in RA, which involves the selection of reference 
centres and a supervision of this difficult procedure at early 
stages of implementation, will improve outcomes, and in 
particular, will reduce complication rates. Further studies are 
needed to evaluate the effects of combining different plaque 
modification techniques including RA as well as high-pressure, 
cutting, and scoring balloons on improvement of early and 
long-term outcomes. Research is also needed to assess an-
other technique for high-speed rotablation, namely orbital 
atherectomy, which was introduced into clinical practice a few 
years ago and has already shown some promising results. It 
is still unclear whether patients can be considered for RA on 
the basis of angiography results only. Selection for RA only 
of patients with PCI failure seems to be limiting the subset 
of patients who might benefit from this treatment. Using 
additional criteria for patient selection on the basis of IVUS, 
OCT, and CT may help identify individuals in whom RA will 
be the most beneficial.
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